CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells-Reference-Cited by-同舟云学术

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells

Published:2024-02-15 Issue:1 Volume:25 Page:
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Wang Hongjie¹,Koob Theo¹,Fromm Jonathan R.²,Gopal Ajay¹,Carter Darrick²,Lieber André¹²³^ORCID

Affiliation:

1. Department of Medicine, University of Washington, Seattle, WA, USA

2. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA

3. R&D, Compliment Corp, Seattle, WA, USA

Funder

National Institutes of Health

Compliment Corp

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2024.2314322

Reference40 articles.

1. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma

2. Isatuximab: First Approval

3. CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma

4. CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents

5. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The complement regulatory protein CD46 serves as a novel biomarker for cervical cancer diagnosis and prognosis evaluation;Frontiers in Immunology;2024-06-11